Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA exonuclease 2 (REXO2) is an evolutionarily conserved exoribonuclease enzyme, primarily localized in mitochondria, that catalyzes the 3′-to-5′ degradation of short RNA oligonucleotides (nanoRNAs) to mononucleotides. REXO2 belongs to the DEDDh-family of nucleases and forms a homodimer, utilizing a two-magnesium-ion-dependent hydrolysis mechanism. It serves a key role in mitochondrial RNA metabolism by "scavenging" short RNAs produced from processing and decay—helping prevent double-stranded RNA accumulation and maintaining mitochondrial transcriptome integrity. Additionally, REXO2 has activity toward short DNA oligonucleotides and may participate in DNA metabolism. No known drugs directly target REXO2; its major biological importance is in RNA turnover, salvage, and mitochondrial function. Knockdown or depletion of REXO2 leads to RNA and DNA metabolic defects, highlighting its essential cellular function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA exonuclease 2 (REXO2).